| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/26/2009 | WO2009038760A2 Human gm-csf antigen binding proteins |
| 03/26/2009 | WO2009038700A1 Diagnosis and treatment of cancer using cancer-testis antigens |
| 03/26/2009 | WO2009038630A1 Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions |
| 03/26/2009 | WO2009038475A1 Systems for expression of heterologous proteins in m. capsulatus |
| 03/26/2009 | WO2009038026A1 Ctl inducer composition |
| 03/26/2009 | WO2009037857A1 Diagnostic agent and therapeutic agent for lung cancer, prostate cancer, breast cancer, ovarian cancer or melanoma |
| 03/26/2009 | WO2009037525A1 Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof |
| 03/26/2009 | WO2009037359A1 Vaccine composition for the prevention of cmv infections |
| 03/26/2009 | WO2009037264A2 Colonic delivery of antimicrobial agents |
| 03/26/2009 | WO2009037262A2 Method of preventing early lawsonia intracellularis infections |
| 03/26/2009 | WO2009036949A1 Hypoallergenic variants of the major allergen from betula verrucosa pollen |
| 03/26/2009 | WO2009036568A1 Methods and compositions for treating tumors and viral infections |
| 03/26/2009 | WO2009020964A3 Anti-neublastin antibodies and uses thereof |
| 03/26/2009 | WO2009020933A3 Therapeutic use of anti-tweak receptor antibodies |
| 03/26/2009 | WO2009015908A3 Anti ephb4 antibodies and antibody fragments |
| 03/26/2009 | WO2009011782A3 METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
| 03/26/2009 | WO2009009116A3 Combination therapies employing gitr binding molecules |
| 03/26/2009 | WO2009009114A3 Compositions and methods for treating and diagnosing cancer |
| 03/26/2009 | WO2009005870A3 Products for prophylaxis and/or treatment of viral diseases and method of making and using same |
| 03/26/2009 | WO2008147496A3 Neuraminidase-deficient live influenza vaccines |
| 03/26/2009 | WO2008112988A3 Apcdd1 inhibitors for treating, diagnosing or detecting cancer |
| 03/26/2009 | WO2008109059A3 Conserved-element vaccines and methods for designing conserved-element vaccines |
| 03/26/2009 | WO2008019186A3 Blood monocyte cd163 expression as a biomarker in hiv-1 infection and neuroaids |
| 03/26/2009 | WO2008010101A8 Antagonist antibody against epha2 for the treatment of cancer |
| 03/26/2009 | WO2007146132A3 Prevention of hiv infection |
| 03/26/2009 | WO2007133250A3 Compositions and methods for diagnosing and treating cancer |
| 03/26/2009 | WO2007025085A3 Genemap of the human genes associated with crohn's disease |
| 03/26/2009 | WO2005117969A3 Solution phase biopanning method using engineered decoy proteins |
| 03/26/2009 | WO2005048917A3 Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer |
| 03/26/2009 | WO2004096993A3 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
| 03/26/2009 | WO2004087733A3 Prevention and treatment of alzheimer amyloid deposition |
| 03/26/2009 | WO2004080387A3 Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins |
| 03/26/2009 | WO2004064612A3 Regulation of tgf-b signaling by tomoregulin |
| 03/26/2009 | US20090082549 Sequence encoding amino acids 301-437 of the Fc region of the mouse immunoglobulin e molecule is genetically fused to pseudomonas exotoxin |
| 03/26/2009 | US20090082444 Compositions for the Treatment of Blood Disorders |
| 03/26/2009 | US20090082296 Mycobacterial antigens expressed during latency |
| 03/26/2009 | US20090082279 Treating a condition associated with breakdown of the blood brain barrier by administering a peptide antagonist of zonulin that binds to the zonula occludens receptor, especially in the brain, yet does not physiologically modulate the opening of mammalian tight junctions |
| 03/26/2009 | US20090082274 Collections of repeat proteins comprising repeat modules |
| 03/26/2009 | US20090081792 Immune potentiating compositions of cancer cells |
| 03/26/2009 | US20090081780 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 03/26/2009 | US20090081732 Antibodies to human il-1beta |
| 03/26/2009 | US20090081728 Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences |
| 03/26/2009 | US20090081725 Compositions of pamps and Listeria monocytogenes and methods of use |
| 03/26/2009 | US20090081667 Viral Variants With Altered Susceptibility To Nucleoside Analogs And Uses Thereof |
| 03/26/2009 | US20090081660 Compositions and methods for the diagnosis and treatment of tumor |
| 03/26/2009 | US20090081284 Therapeutic agent for allergy containing liposome having oligosaccharide on its surface |
| 03/26/2009 | US20090081283 Tumor therapy with non-viral-based high affinitiy laminin receptor-targeted vectors |
| 03/26/2009 | US20090081258 Kennel cough vaccine |
| 03/26/2009 | US20090081257 Hydrogenase deficient bacterial strains |
| 03/26/2009 | US20090081256 Transgenic plant-based vaccines |
| 03/26/2009 | US20090081255 under any circumstances, in a short period of time and in large amount; vaccine; immunizing a hen by administering a flu vaccine to hen to trigger embryogenesis in its eggs, infecting the embryonated eggs by inoculating a flu virus into the allantoic cavity, incubating, harvesting the allantoic fluid |
| 03/26/2009 | US20090081254 Hiv vaccine for mucosal delivery |
| 03/26/2009 | US20090081253 Composition |
| 03/26/2009 | US20090081252 Decreasing potential iatrogenic risks associated with influenza vaccines |
| 03/26/2009 | US20090081250 Compositions and methods for treatment of cervical cancer |
| 03/26/2009 | US20090081249 Bi-Functional Polymer-Attached Inhibitors of Influenza Virus |
| 03/26/2009 | US20090081248 Non-hemolytic LLO fusion proteins and methods of utilizing same |
| 03/26/2009 | US20090081247 Immune adjuvant comprising ATP |
| 03/26/2009 | US20090081246 Method for isolating hepatitis c virus peptides |
| 03/26/2009 | US20090081245 Assays for development of boris mutants suitable for vaccine development and small molecule inhibitors of wild-type boris |
| 03/26/2009 | US20090081244 Dry Formulation for Transcutaneous Immunization |
| 03/26/2009 | US20090081243 Agents and methods for diagnosing stress |
| 03/26/2009 | US20090081242 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 03/26/2009 | US20090081241 comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein |
| 03/26/2009 | US20090081240 Human Anti-Kir Antibodies |
| 03/26/2009 | US20090081239 bind and neutralize Plasminogen Activator Inhibitor-1 (PAI-1) by converting PAI-1 to its latent form or increasing proteolytic cleavage; treating a fibrotic condition; inhibits accumulation of extracellular matrix (ECM) |
| 03/26/2009 | US20090081238 Anti-notch1 NRR antibodies and methods using same |
| 03/26/2009 | US20090081237 Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents |
| 03/26/2009 | US20090081236 Immunizing compositions and methods of use |
| 03/26/2009 | US20090081235 Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response |
| 03/26/2009 | US20090081234 administering a composition comprising an effective amount of at least one isolated mammalian anti-tumor necrosis factor (TNF) antibody comprising at least one variable region comprising SEQ ID NO:7 and 8 |
| 03/26/2009 | US20090081233 Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| 03/26/2009 | US20090081232 Methods of treating diseases with anti-vegf antibodies |
| 03/26/2009 | US20090081231 Methods and compositions for use in treatment of patients with autoantibody positive disease |
| 03/26/2009 | US20090081230 Human cytomegalovirus neutralising antibodies and use thereof |
| 03/26/2009 | US20090081229 Anti-pro87299 antibodies |
| 03/26/2009 | US20090081228 Cyr61 compositions and methods |
| 03/26/2009 | US20090081227 Promotong differentiation of neural stem cells to nerve cells for use in treating injury to central nerve system caused by brain infarction, hemorrhage and/or spinal cord injury |
| 03/26/2009 | US20090081226 Soluble HLA-E Molecules And Their Use For Diagnosing And Treating Pathologies |
| 03/26/2009 | US20090081225 PIF peptides biologic activities, site of action, and the antibody to detect PIF |
| 03/26/2009 | US20090081224 Compositions of polypeptides specific to pathogenic strains and their use as vaccines and in immunotheraphy |
| 03/26/2009 | US20090081223 Fixed dosing of her antibodies |
| 03/26/2009 | US20090081222 Novel splice variants of the egf receptor |
| 03/26/2009 | US20090081221 Method for suppressing cancer cell metastasis and pharmaceutical composition for use in the method |
| 03/26/2009 | US20090081220 Method for diagnosing and treatment of breast cancer and pharmaceuticals composition and kit for same |
| 03/26/2009 | US20090081219 Human monoclonal antibodies against CD25 |
| 03/26/2009 | US20090081218 Fusion proteins |
| 03/26/2009 | US20090081217 Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties |
| 03/26/2009 | US20090081216 Treatment of pathologies which escape the immune response, using optimized antibodies |
| 03/26/2009 | US20090081215 Genetic products differentially expressed in tumors and use thereof |
| 03/26/2009 | US20090081214 Genetic products differentially expressed in tumors and use thereof |
| 03/26/2009 | US20090081213 Methods and compositions for use in treatment of patients with autoantibody positive disease |
| 03/26/2009 | US20090081212 Use and targeting of cd98 light-chain proteins in therapies for thyroid hormone disorders |
| 03/26/2009 | US20090081211 C3b antibodies and methods for the prevention and treatment of complement-associated disorders |
| 03/26/2009 | US20090081210 Methods of Killing Tumor Cells by Targeting Internal Antigens Exposed on Apoptotic Tumor Cells |
| 03/26/2009 | US20090081209 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins |
| 03/26/2009 | US20090081208 Optimized Fc variants and methods for their generation |
| 03/26/2009 | US20090081207 High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity |
| 03/26/2009 | US20090081206 Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals |
| 03/26/2009 | US20090081205 Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents |